Column

Global Newsletter

China: Preferential policies related to drug application registration by using Real-World Evidence (RWE) in Hainan Medical Pilot

The National Medical Products Administration in China is actively exploring the use of clinical real-world evidence (RWE) data for medical device product registration.

• China
• Medical Equipment
• New Trends

Global Newsletter

Change in China’s Regulatory Affairs

In November 2018, the Chinese State Medical Insurance Administration officially announced a trial plan for centralized drug procurement, the so-called “4+7 Plan”. We will check out what this policy and other changes in China's changing pharmaceutical regulations have in store for foreign innovators.

• China
• Approval